Bli medlem
Bli medlem

Du är här

2016-11-28

Biocartis Group NV: Disclosure of a transparency notification

PRESS RELEASE: REGULATED INFORMATION

28 November 2016, 07:00 CET

Disclosure of a transparency notification

(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of
major shareholdings)

Mechelen, Belgium, 28 November 2016
- Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular
diagnostics company (Euronext Brussels: BCART), announces today in accordance
with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the
disclosure of major shareholdings in issuers whose shares are admitted to
trading on a regulated market (the 'Belgian Transparency Act'), that it
received a transparency notification dated 22 November 2016 (the
'Notification'), indicating that the shareholding of DHAM NV (which is
controlled by KORYS NV, which is in turn controlled by Stichting
Administratiekantoor Cozin) has decreased below the 3% notification
threshold.

The Notification contains the following information:

* Reason for the Notification : passive downward crossing of the lowest
threshold.
* Notification by : a parent undertaking or a controlling person.
* Persons subject to the notification requirement : DHAM NV, G. Gezellestraat
126, 1654 Huizingen, Belgium, KORYS NV, G. Gezellestraat 126, 1654
Huizingen, Belgium and Stichting Administratiekantoor Cozin, Claude
Debussylaan 24, 1085 MD Amsterdam, The Netherlands.
* Transaction date : 17 November 2016.
* Threshold that is crossed : 3%.
* Denominator : 44,648,105.
* Chain of controlled undertakings through which the holding was effectively
held :

DHAM NV is controlled by KORYS NV, which is controlled by Stichting
Administratiekantoor Cozin. Stichting Administratiekantoor Cozin is not a
controlled entity.

The Notification is availablehereon the website of the Company.

Pursuant to the Belgian Transparency Act and the articles of association of
the Company, a notification to the Company and the Belgian Financial Services
and Markets Authority ('FSMA') is required by all natural and legal persons
in each case where the percentage of voting rights in the Company held by
such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%,
and every subsequent multiple of 5%, of the total number of voting rights in
the Company.

----- END ----

More information:

Renate Degrave
Manager Corporate Communications&Investor Relations
e-mail rdegrave@biocartis.com

tel +32 15 631 729
mobile +32 471 53 60 64

About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at
improving clinical practice for the benefit of patients, clinicians, payers
and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system
that offers accurate, highly reliable molecular information from virtually
any biological sample in virtually any setting. Biocartis launched the
Idylla(TM) platform in September 2014. Biocartis is developing and marketing
a rapidly expanding test menu addressing key unmet clinical needs in oncology
and infectious diseases. These areas represent respectively the fastest
growing and largest segments of the MDx market worldwide. Today, Biocartis
has five oncology tests and two infectious disease tests on the market. More
information: www.biocartis.com.Press Photo Library availablehere. Follow us
onTwitter: @Biocartis_.

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.